title: Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial.
abstract: OBJECTIVE
  We prospectively evaluated the amino acid analogue positron emission tomography radiotracer anti-3-[(18)F]FACBC compared to ProstaScint® ((111)In-capromab pendetide) single photon emission computerized tomography-computerized tomography to detect recurrent prostate carcinoma.
  
  
  METHODS
  A total of 93 patients met study inclusion criteria who underwent anti-3-[(18)F]FACBC positron emission tomography-computerized tomography plus (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for suspected recurrent prostate carcinoma within 90 days. Reference standards were applied by a multidisciplinary board. We calculated diagnostic performance for detecting disease.
  
  
  RESULTS
  In the 91 of 93 patients with sufficient data for a consensus on the presence or absence of prostate/bed disease anti-3-[(18)F]FACBC had 90.2% sensitivity, 40.0% specificity, 73.6% accuracy, 75.3% positive predictive value and 66.7% negative predictive value compared to (111)In-capromab pendetide with 67.2%, 56.7%, 63.7%, 75.9% and 45.9%, respectively. In the 70 of 93 patients with a consensus on the presence or absence of extraprostatic disease anti-3-[(18)F]FACBC had 55.0% sensitivity, 96.7% specificity, 72.9% accuracy, 95.7% positive predictive value and 61.7% negative predictive value compared to (111)In-capromab pendetide with 10.0%, 86.7%, 42.9%, 50.0% and 41.9%, respectively. Of 77 index lesions used to prove positivity histological proof was obtained in 74 (96.1%). Anti-3-[(18)F]FACBC identified 14 more positive prostate bed recurrences (55 vs 41) and 18 more patients with extraprostatic involvement (22 vs 4). Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography correctly up-staged 18 of 70 cases (25.7%) in which there was a consensus on the presence or absence of extraprostatic involvement.
  
  
  CONCLUSIONS
  Better diagnostic performance was noted for anti-3-[(18)F]FACBC positron emission tomography-computerized tomography than for (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for prostate carcinoma recurrence. The former method detected significantly more prostatic and extraprostatic disease.
authors.affiliation: Department of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia. Electronic address: dschust@emory.edu.
authors.forename: David M
authors.initials: DM
authors.lastname: Schuster
authors.affiliation: Department of Urology, Emory University, Atlanta, Georgia.
authors.forename: Peter T
authors.initials: PT
authors.lastname: Nieh
authors.affiliation: Department of Radiation Oncology, Emory University, Atlanta, Georgia.
authors.forename: Ashesh B
authors.initials: AB
authors.lastname: Jani
authors.affiliation: Department of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia.
authors.forename: Rianot
authors.initials: R
authors.lastname: Amzat
authors.affiliation: Department of Biostatistics and Bioinformatics, Emory University, Atlanta, Georgia.
authors.forename: F Dubois
authors.initials: FD
authors.lastname: Bowman
authors.affiliation: Department of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia.
authors.forename: Raghuveer K
authors.initials: RK
authors.lastname: Halkar
authors.affiliation: Department of Urology, Emory University, Atlanta, Georgia.
authors.forename: Viraj A
authors.initials: VA
authors.lastname: Master
authors.affiliation: Department of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia.
authors.forename: Jonathon A
authors.initials: JA
authors.lastname: Nye
authors.affiliation: Department of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia.
authors.forename: Oluwaseun A
authors.initials: OA
authors.lastname: Odewole
authors.affiliation: Department of Urology, Emory University, Atlanta, Georgia; Department of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia.
authors.forename: Adeboye O
authors.initials: AO
authors.lastname: Osunkoya
authors.affiliation: Department of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia.
authors.forename: Bital
authors.initials: B
authors.lastname: Savir-Baruch
authors.affiliation: Department of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia.
authors.forename: Pooneh
authors.initials: P
authors.lastname: Alaei-Taleghani
authors.affiliation: Department of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia.
authors.forename: Mark M
authors.initials: MM
authors.lastname: Goodman
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal; D002264:Carboxylic Acids; D002277:Carcinoma / Q000175:diagnosis*; D003503:Cyclobutanes; D006801:Humans; D007205:Indium Radioisotopes; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis*; D049268:Positron-Emission Tomography; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000175:diagnosis*; D015899:Tomography, Emission-Computed, Single-Photon; D014057:Tomography, X-Ray Computed
chemical_list: D000911:Antibodies, Monoclonal; D002264:Carboxylic Acids; D003503:Cyclobutanes; D007205:Indium Radioisotopes; C117460:fluciclovine F-18; C101315:Capromab Pendetide
keywords: 1-amino-3-fluorocyclobutane-1-carboxylic acid; capromab pendetide; emission-computed; photon; positron-emission tomography; prostatic neoplasms; tomography